On 23 December 2025, QingSong Health Corporation (QingSong Health, 2661.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 602 million. CBI is honored to participate in the due diligence work for this IPO Project.

QingSong Health is a company primarily engaged in the provision of digital integrated healthcare and health insurance solutions. The Company operates three businesses. The healthcare-related services business is primarily engaged in the provision of digital marketing (market education services), digital medical research assistance, integrated health service packages, early disease screening related promotion and consultancy, medical appointment services and health supplement sales. The insurance-related services business is primarily engaged in the provision of insurance brokerage service and insurance technical services such as the development of management platform for insurance product operations. The other services business is primarily engaged in the provision of online and offline marketing services.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers and suppliers, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence and related company search. The due diligence project globally covered 8 countries and regions, including China, Hong Kong, Singapore, the United Kingdom and Canada, etc.